Genmab axes development of AXL-targeting cancer drug enapotamab vedotinGenmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity Share XGenmab axes development of AXL-targeting cancer drug enapotamab vedotinhttps://pharmaphorum.com/news/genmab-axes-development-axl-targeting-cancer-drug-enapotamab-vedotin/
BerGenBio raises 45 million euros for COVID-19 drug developmentNorway’s BerGenBio has raised 500 million Norwegian kroner – around $45.4 million euros – in an oversubscribed private placement to Share XBerGenBio raises 45 million euros for COVID-19 drug developmenthttps://pharmaphorum.com/news/bergenbio-raises-45-million-euros-for-covid-19-drug-development/
UK initiative aims to cut COVID-19 drug development to a few weeksA new UK trial initiative aims to cut the design phase of clinical studies for potential COVID-19 drugs from around 18 Share XUK initiative aims to cut COVID-19 drug development to a few weekshttps://pharmaphorum.com/news/uk-initiative-aims-to-cut-covid-19-drug-development-to-a-few-weeks/
